Fanhua BluePlus Forming Strategic Partnerships with Shanghai Biotecan Pharmaceuticals
Fanhua Inc. (Nasdaq: FANH), a leading independent technology-driven financial services provider in China, has announced a strategic partnership between its subsidiary Fanhua BluePlus Health Management Co., and Shanghai Biotecan Pharmaceuticals Co. The collaboration aims to leverage their respective strengths in cutting-edge medical testing, health management, and cell therapy.
Qiao Yu, CEO of Fanhua BluePlus, expressed excitement about the partnership, highlighting Biotecan's pioneering role in clinical molecular diagnostics and biomedicine in China. The agreement underscores Fanhua's commitment to meeting customers' needs for high-quality life and comprehensive healthcare solutions. As a one-stop health and wellness service platform provider, Fanhua BluePlus plans to continue seeking partnerships with top biopharmaceutical enterprises to connect health service providers with clients.
Fanhua Inc. (Nasdaq: FANH), un fornitore indipendente di servizi finanziari tecnologici leader in Cina, ha annunciato una partnership strategica tra la sua sussidiaria Fanhua BluePlus Health Management Co. e Shanghai Biotecan Pharmaceuticals Co. La collaborazione mira a sfruttare i rispettivi punti di forza in test medici all'avanguardia, gestione della salute e terapia cellulare.
Qiao Yu, CEO di Fanhua BluePlus, ha espresso entusiasmo per la partnership, evidenziando il ruolo innovativo di Biotecan nella diagnostica molecolare clinica e nella biomedicina in Cina. L'accordo sottolinea l'impegno di Fanhua nel soddisfare le esigenze dei clienti per una vita di alta qualità e soluzioni sanitarie complete. Come fornitore di una piattaforma unica per i servizi di salute e benessere, Fanhua BluePlus prevede di continuare a cercare partnership con importanti imprese biopharmaceutical per connettere i fornitori di servizi sanitari con i clienti.
Fanhua Inc. (Nasdaq: FANH), un proveedor independiente líder de servicios financieros impulsados por la tecnología en China, ha anunciado una asociación estratégica entre su subsidiaria Fanhua BluePlus Health Management Co. y Shanghai Biotecan Pharmaceuticals Co. La colaboración tiene como objetivo aprovechar sus respectivas fortalezas en pruebas médicas de vanguardia, gestión de la salud y terapia celular.
Qiao Yu, CEO de Fanhua BluePlus, expresó su entusiasmo por la asociación, destacando el papel pionero de Biotecan en el diagnóstico molecular clínico y la biomedicina en China. El acuerdo subraya el compromiso de Fanhua de satisfacer las necesidades de sus clientes en cuanto a calidad de vida y soluciones integrales de atención médica. Como proveedor de una plataforma de servicios de salud y bienestar integral, Fanhua BluePlus planea continuar buscando asociaciones con empresas biofarmacéuticas de primer nivel para conectar a los proveedores de servicios de salud con los clientes.
Fanhua Inc. (Nasdaq: FANH)는 중국의 선도적인 독립 기술 기반 금융 서비스 제공업체로, 자회사인 Fanhua BluePlus Health Management Co.와 상하이 Biotecan Pharmaceuticals Co. 간의 전략적 파트너십을 발표했습니다. 이번 협업은 최첨단 의료 테스트, 건강 관리 및 세포 치료에서 각자의 강점을 활용하는 것을 목표로 하고 있습니다.
Fanhua BluePlus의 CEO인 Qiao Yu는 파트너십에 대한 기대감을 표명하며, Biotecan의 중국 내 임상 분자 진단 및 생의학 분야에서의 개척자 역할을 강조했습니다. 이 합의는 고객의 고품질 삶 및 종합적인 건강 관리 솔루션에 대한 Fanhua의 의지를 강조합니다. Fanhua BluePlus는 원스톱 건강 및 웰빙 서비스 플랫폼 제공업체로서, 건강 서비스 제공자를 고객과 연결하기 위해 최고의 바이오제약 기업과의 파트너십을 지속적으로 모색할 계획입니다.
Fanhua Inc. (Nasdaq: FANH), un fournisseur indépendant de services financiers axés sur la technologie et leader en Chine, a annoncé un partenariat stratégique entre sa filiale Fanhua BluePlus Health Management Co. et Shanghai Biotecan Pharmaceuticals Co. Cette collaboration vise à tirer parti de leurs forces respectives en tests médicaux de pointe, gestion de la santé et thérapie cellulaire.
Qiao Yu, PDG de Fanhua BluePlus, a exprimé son enthousiasme pour ce partenariat, mettant en avant le rôle pionnier de Biotecan dans le diagnostic moléculaire clinique et la biomédecine en Chine. Cet accord souligne l'engagement de Fanhua à répondre aux besoins de ses clients en matière de qualité de vie et de solutions de soins de santé complètes. En tant que fournisseur d'une plateforme de services de santé et de bien-être tout-en-un, Fanhua BluePlus prévoit de continuer à rechercher des partenariats avec des entreprises biopharmaceutiques de premier plan pour connecter les prestataires de services de santé avec les clients.
Fanhua Inc. (Nasdaq: FANH), ein führender unabhängiger technologiegetriebener Finanzdienstleister in China, hat eine strategische Partnerschaft zwischen seiner Tochtergesellschaft Fanhua BluePlus Health Management Co. und Shanghai Biotecan Pharmaceuticals Co. bekannt gegeben. Die Zusammenarbeit zielt darauf ab, die jeweiligen Stärken in modernster medizinischer Testung, Gesundheitsmanagement und Zelltherapie zu nutzen.
Qiao Yu, der CEO von Fanhua BluePlus, äußerte sich begeistert über die Partnerschaft und hob Biotecans Pionierrolle in der klinischen molekularen Diagnostik und Biomedizin in China hervor. Der Vertrag unterstreicht Fanhuas Engagement, die Bedürfnisse der Kunden nach hochwertigem Leben und umfassenden Gesundheitslösungen zu erfüllen. Als Anbieter einer ganzheitlichen Gesundheits- und Wellnessdienstleistungsplattform plant Fanhua BluePlus, weiterhin Partnerschaften mit führenden biopharmazeutischen Unternehmen zu suchen, um Gesundheitsdienstleister mit Kunden zu verbinden.
- Strategic partnership with Biotecan, a leader in clinical molecular diagnostics and biomedicine
- Expansion into high-end medical and health management services
- Potential for increased customer base and service offerings
- None.
Insights
This strategic partnership between Fanhua BluePlus and Biotecan marks a significant step in integrating advanced medical technologies with health management services. The collaboration focuses on cutting-edge medical testing, health management and cell therapy, which are at the forefront of personalized medicine. This move could potentially enhance Fanhua's service offerings and expand its market reach in the rapidly growing health management sector in China.
However, it's important to note that the financial impact of this partnership is not immediately quantifiable. The success will largely depend on the effective integration of Biotecan's diagnostic expertise with Fanhua's customer base and distribution network. Investors should monitor for future updates on revenue generation and market penetration resulting from this collaboration.
This partnership aligns with the growing trend of health-tech convergence in China's healthcare market. With an aging population and increasing health awareness, there's a rising demand for comprehensive health management services. Fanhua's move to partner with a clinical diagnostics leader like Biotecan could potentially differentiate its offerings in a competitive market.
However, the success of this venture will depend on factors such as regulatory compliance, consumer adoption of high-end health services and the scalability of the combined offerings. While the partnership shows promise, investors should look for concrete metrics in future reports, such as customer acquisition costs, retention rates and revenue per customer, to gauge the actual impact on Fanhua's financial performance.
GUANGZHOU, China, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Fanhua Inc. (Nasdaq: FANH) (the “Company” or “FANHUA”), a leading independent technology-driven financial services provider in China, today announced that it, through its wholly-owned subsidiary Fanhua BluePlus Health Management Co., Ltd. (“Fanhua BluePlus”) has recently signed a strategic cooperation agreement with Shanghai Biotecan Pharmaceuticals Co. Ltd. (“Biotecan”).
Pursuant to the strategic cooperation agreement, Fanhua BluePlus and Biotecan will leverage their respective resources and service strengths to collaborate on cutting-edge medical testing, health management, cell therapy, and other modern high-end medical and health management services.
Commenting on the agreement, Chief Executive Officer of Fanhua BluePlus Mr. Qiao Yu said, “We are excited about our strategic cooperation with Biotecan, a pioneer in clinical molecular diagnostics and biomedicine in China. It fully demonstrates our commitment to meeting customers' needs for a high-quality life. We look forward to working with Biotecan to safeguard our customers' health and well-being. As a one-stop health and wellness service platform provider, we will continue to seek partnership with top biopharmaceutical enterprises to connect health and wellness service providers with biopharmaceutical enterprises and to provide more clients with comprehensive healthcare solutions.”
About Fanhua BluePlus
Fanhua BluePlus Health Management Co., Ltd., a one-stop wellness service platform under Fanhua Inc., was established in 2010 and has been deeply involved in the industry for 13 years. With partnerships with over 110 top domestic medical, wellness, and financial institutions, Fanhua BluePlus provides health and wellness services to more than 50,000 clients annually. The platform offers a comprehensive product matrix that fully addresses clients’ needs across “prevention, medical care, nursing, health maintenance, and elder care”.
About Biotecan
Established in 2008, Shanghai Biotecan Pharmaceuticals Co. Ltd. has over 20 subsidiaries and is a pioneer in clinical molecular diagnostics in China. It has partnered with more than 120 Grade-III Class-A hospitals nationwide to establish molecular medical centers, providing precision medical molecular diagnostics and clinical research services to over 1,000 hospitals. The in-hospital laboratory network created by Biotecan offers more than 2,000 precision medical services covering oncology, chronic diseases, maternal and child health, infectious diseases, intestinal microbiome diseases, and general health exams. Over 200 million Biotecan’s visitors receive outpatient and emergency treatments per year.
About Fanhua
Established in Guangzhou in 1998 and listed on NASDAQ in 2007 (Nasdaq: FANH), Fanhua is a leading independent financial services provider in China with strong technology capabilities and a commitment to empowering financial advisors and fostering sustained value creation for customers.
Our mission revolves around creating an inclusive and collaborative platform for independent financial advisors, as well as various insurance/financial sales organizations, enabling our partners to optimize their practices by offering them end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow, and professional training.
Leveraging advanced technology, artificial intelligence, and data-driven insights, Fanhua is at the forefront of revolutionizing financial services delivery, accelerating digital transformation, and driving industry growth.
With a comprehensive approach to financial services, we connect millions of Chinese families with various financial institutions and service providers, offering a diverse range of opportunities and personalized solutions for insurance protection, retirement planning, health management, asset management, and family governance services, covering the full lifecycle of our customers’ needs.
Forward-looking Statements
This press release contains statements of a forward-looking nature. These statements, including the statements relating to the Company’s future financial and operating results, are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will", "expects", "believes", "anticipates", "intends", "estimates" and similar statements. Among other things, management’s quotations contain forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Fanhua and the industry. Potential risks and uncertainties include, but are not limited to, those relating to its ability to attract and retain productive agents, especially entrepreneurial agents, its ability to maintain existing and develop new business relationships with insurance companies, its ability to execute its growth strategy, its ability to adapt to the evolving regulatory environment in the Chinese insurance industry, its ability to compete effectively against its competitors, quarterly variations in its operating results caused by factors beyond its control and macroeconomic conditions in China and their potential impact on the sales of insurance products. Except as otherwise indicated, all information provided in this press release speaks as of the date hereof, and Fanhua undertakes no obligation to update any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although Fanhua believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. Further information regarding risks and uncertainties faced by Fanhua is included in Fanhua’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.
For more information, please contact:
Fanhua Inc.
Investor Relations
Tel: +86 (20) 8388-3191
Email: ir@fanhgroup.com
Source: Fanhua Inc.
FAQ
What is the new strategic partnership announced by Fanhua Inc. (FANH)?
How will the partnership between Fanhua BluePlus and Biotecan benefit customers?
What are Fanhua BluePlus's future plans regarding partnerships in the healthcare sector?
